Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 32 (Valrubicin) in BCG-Refractory Bladder Cancer
NCT00003129Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Sep 1998
- Primary completion
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valrubicin in bladder cancer, sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Recurrence Rate and Disease Free Survival. Started Sep 1998; status: completed.
02
Drugs
valrubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00003129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003129.